Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class ...

Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class ...

In separate cat and birch allergen-challenge trials, single doses of allergen-specific antibody blockers significantly reduced allergy symptoms compared to placebo

Regeneron’s promising antibody for cat, birch allergies; Ascletis targets quarterly GLP-1 shot

Plus, news about Anavex, Alnylam, Rapport Therapeutics, Dianthus Therapeutics, Ultragenyx, Atom Therapeutics, Alchemab, BioMarin, Amgen, Kyowa Kirin and Bristol Myers Squibb: 🤧 Regeneron’s allergy drugs clear Phase 3 trials: The company’s allergen-blocking antibody candidates ...